Anzeige
Mehr »
Login
Samstag, 02.03.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
High-Grade News! Heute wieder ein 57% Kursspektakel?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856273 | ISIN: JP3942400007 | Ticker-Symbol: YPH
Tradegate
01.03.24
15:39 Uhr
10,405 Euro
+0,040
+0,39 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
ASTELLAS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASTELLAS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,27010,45501.03.
10,26010,47001.03.

Aktuelle News zur ASTELLAS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.02.Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m4
16.02.Astellas's CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies5
16.02.Astellas teams up with startup Kelonia to make 'in vivo' cell therapies3
16.02.Japan grants priority review for Astellas' urothelial cancer regimen4
16.02.Astellas pledges $800m to Kelonia CAR-T alliance in cancer3
13.02.Pfizer wins pharma ad Super Bowl, beating Astellas' Veozah spot18
08.02.Astellas adds digital to its top management team3
07.02.ASTELLAS PHARMA INC.: Astellas Makes Announcement about Management Structure398TOKYO, Feb. 6, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its management structure effective April...
► Artikel lesen
05.02.Astellas' sales expectations are up for Padcev, down for Veozah8
05.02.Astellas Pharma GAAP EPS of ¥67.20, revenue of ¥1.18B11
05.02.Amgen, Astellas backed group wants patients to test their biomarkers in new stomach cancer campaign5
05.02.Astellas raises Padcev forecasts on bladder cancer data6
01.02.Astellas inks deal to air Veozah ad in Super Bowl 2024 coverage3
31.01.Astellas seeks approval for Padcev-Keytruda combo therapy in Japan4
31.01.Astellas collaborates with Mass General Brigham for translational medicine3
31.01.Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment325KENILWORTH (NJ) (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the submission of a Supplemental New Drug Application or sNDA to Japan's Ministry of Health, Labour and Welfare for...
► Artikel lesen
31.01.Astellas Pharma Announces Collaboration With Mass General Brigham329TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that it has reached a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development...
► Artikel lesen
29.01.Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda14
29.01.EMA validates Pfizer-Astellas' bladder cancer therapy application for review14
26.01.Astellas Pharma Inc.: European Medicines Agency Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer535- Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival - - If approved, PADCEV with KEYTRUDA would be the first combination...
► Artikel lesen
Seite:  Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2